Orforglipron for Weight Loss — Weight & Metabolism
Once-daily oral GLP-1 receptor agonist for substantial weight reduction without injections.
Overview
Orforglipron is a novel once-daily oral, non-peptide GLP-1 receptor agonist developed by Eli Lilly. Phase 3 trials (ATTAIN-1) demonstrated 11-12% weight loss over 72 weeks with 54% of participants achieving ≥10% weight loss. With 79% bioavailability and no food/water restrictions, it offers a convenient alternative to injectable GLP-1s.
Indications
- Obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities
- Type 2 diabetes with weight management goals
- Patients seeking non-injectable GLP-1 therapy
- Long-term weight management and metabolic optimization
Mechanism of Action
Excess weight and poor glucose control drive appetite dysregulation and metabolic disease progression
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Orforglipron | 6 mg | Once daily (any time, no food restrictions) | Entry dose: 7.5-7.8% weight loss over 72 weeks |
| Orforglipron | 12 mg | Once daily (any time, no food restrictions) | Mid-range dose: 8.4-9.3% weight loss, good efficacy/tolerability balance |
| Orforglipron | 36 mg | Once daily (any time, no food restrictions) | Highest dose: 11.2-12.4% weight loss, 54.6% achieve ≥10% loss |
Safety & Contraindications
- Phase 3 trials completed, regulatory submission anticipated (not yet FDA approved)
- Common GI side effects during dose escalation (nausea 29-36%, diarrhea 19-26%)
- Discontinuation rate 10-17% due to adverse events (mostly GI-related)
- No hepatic safety signals observed in clinical trials
- Pulse increases observed (typical for GLP-1 class)